Granulomatous hepatitis after intravesical BCG treatment for bladder cancer

Indian J Gastroenterol. 2006 Sep-Oct;25(5):258-9.

Abstract

Intravesical bacillus Calmette-Guerin (BCG) is used in patients with urinary bladder carcinoma. Although it is generally well tolerated, granulomatous hepatitis is a rare but serious complication. We report a 42-year-old man and a 56-year-old man who developed granulomatous hepatitis following intravesical BCG. One of them was treated successfully with antitubercular therapy; the other died because of BCG sepsis and multi-organ failure.

Publication types

  • Case Reports

MeSH terms

  • Administration, Intravesical
  • Adult
  • Antitubercular Agents / therapeutic use
  • BCG Vaccine / adverse effects*
  • Biopsy, Needle
  • Carcinoma, Transitional Cell / drug therapy*
  • Fatal Outcome
  • Humans
  • Liver / microbiology
  • Liver / pathology
  • Male
  • Middle Aged
  • Tuberculosis, Hepatic / drug therapy
  • Tuberculosis, Hepatic / microbiology*
  • Urinary Bladder Neoplasms / drug therapy*

Substances

  • Antitubercular Agents
  • BCG Vaccine